Chitosan is a nontoxic and bioabsorbable polymer that has been investigated for a broad range of drug delivery applications (1-4). SQZgelTM are tablets that are a blend of chitosan and polyethylene glycol (PEG) and are used as a controlled-release oral formulation. The technology was developed by MacroMed, Inc. that was recently acquired by Protherics, PLC and is based on a pH sensitive inner core surrounded by a nondegradable microporous coated tablet (5,6). SQZgel tablets permit once or twice daily dosing and are designed to enhance patient compliance, reduce peak to trough blood levels, and eliminate the requirement of 4-6 doses daily.